DelveInsight's 'Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of OM in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Oral Mucositis (OM) from 2017 to 2028 segmented by G8 Countries market. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

• China

Study Period: 2017-2028

Oral Mucositis (OM) - Disease Understanding and Treatment Algorithm

The DelveInsight Oral Mucositis (OM) market report gives the thorough understanding of the Oral Mucositis by including details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Oral Mucositis in the US, Europe, Japan, and China.

Oral Mucositis Epidemiology

The Oral Mucositis (OM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for G8 countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Diagnosed Incident cases, Grade-specific cases, Risk Factor Associated cases), scenario of Oral Mucositis (OM) in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) Japan and China from 2017-2028.

According to DelveInsight, total diagnosed incident population of Oral Mucositis (OM) in G8 countries markets was found to be 5,333,193 in 2017

Oral Mucisitis Drug Chapters

This segment of the Oral Mucositis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic market of G8 Countries is driven majorly by Kepivance, Magic mouthwash, approved mouth rinse (Episil (SP-03), Gelx, Neutrasal, ProThelial, Mucotrol and Painkillers. Detailed chapter for upcoming therapies like EC-18 (Enzychem Lifesciences Corporation), SGX942 (Soligenix Inc.), OPC-12759 (Otsuka Pharmaceuticals), RRx-001 (EpicentRx), AG013 (Oragenics, Inc.), Validive (Monopar Therapeutics), GC4419 (Galera Therapeutics), SAMITAL (Indena S.p.A), Brilacidin (Innovation Pharmaceuticals), Mucomel (Spherium Biomed) and Folotyn and Leucovorin have been covered in the report.

Oral Mucositis Market Outlook

The Oral Mucositis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Oral Mucositis in G8 countries was found to be USD 638.8 Million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Oral Mucositis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Oral Mucositis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Oral Mucositis Report Key Strengths

• 10 Year Forecast

• G8 Countries Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Oral Mucositis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Oral Mucositis market

• Organize sales and marketing efforts by identifying the best opportunities for Oral Mucositis market

• To understand the future market competition in the Oral Mucositis market.

1. Key Insights

2. The Report contains:

3. Oral Mucositis Market: Overview at a Glance

3.1. Market Share Distribution of OM in 2018

3.2. Market Share Distribution of OM in 2028

4. Oral Mucositis (OM): Disease Background and Overview

4.1. Introduction

4.2. Symptoms

4.3. Etiology

4.4. Risk Factors of Oral Mucositis

4.5. Pathophysiology

4.6. Diagnosis of Oral Mucositis

4.7. Clinical Oral Mucositis Assessment Scales

4.8. World Health Organization (WHO) scale for oral mucositis

4.9. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

4.10. References

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Diagnosed Incident Cases of Oral Mucositis in G8 Countries

6. Country-Specific Epidemiology of Oral Mucositis

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Diagnosed Incident Population of Oral Mucositis in the United States

6.1.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the United States

6.1.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in the United States

6.2. EU5

6.2.1. Assumptions and Rationale

6.3. Germany

6.3.1. Diagnosed Incident Population of Oral Mucositis in Germany

6.3.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Germany

6.3.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Germany

6.4. France

6.4.1. Diagnosed Incident Population of Oral Mucositis in France

6.4.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in France

6.4.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in France

6.5. Italy

6.5.1. Diagnosed Incident Population of Oral Mucositis in Italy

6.5.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Italy

6.5.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Italy

6.6. Spain

6.6.1. Diagnosed Incident Population of Oral Mucositis in Spain

6.6.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Spain

6.6.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Spain

6.7. United Kingdom

6.7.1. Diagnosed Incident Population of Oral Mucositis in the United Kingdom

6.7.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the United Kingdom

6.7.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in the United Kingdom

6.8. Japan

6.8.1. Assumptions and Rationale

6.8.2. Diagnosed Incident Population of Oral Mucositis in Japan

6.8.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Japan

6.8.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Japan

6.9. China

6.9.1. Assumptions and Rationale

6.9.2. Diagnosed Incident Population of Oral Mucositis in China

6.9.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in China

6.9.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in China

7. Current Treatment Practices

7.1. Chemotherapy Induced Oral Mucositis Treatment and Prevention

7.2. MASCC/ISOO Guideline Recommendations

7.3. Treatment and Prevention Options for Patients receiving Hematopoietic Stem Cell Transplantation (HSCT)

7.4. Radiotherapy Induced Oral Mucositis Treatment and Prevention

7.5. Treatment of Oral Mucositis and Oral Complications

7.6. UKOMiC (United Kingdom Oral Mucositis in Cancer Group)

7.7. ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

8. Unmet Needs

9. Marketed Drugs

9.1. Key cross competition- Marketed Drugs

9.2. Gelclair: Helsinn Healthcare

9.2.1. Drug Description

9.2.2. Regulatory Milestones

9.2.3. Product Profile

9.3. Caphosol: EUSA Pharma/Canbridge Life Sciences

9.3.1. Drug Description

9.3.2. Regulatory Milestones

9.3.3. Clinical Development

9.3.4. Safety and Efficacy

9.3.5. Product Profile

9.4. Episil: Solasia Pharma / Camurus AB

9.4.1. Drug Description

9.4.2. Regulatory Milestones

9.4.3. Clinical Development

9.4.4. Product Profile

9.5. MuGard: Access Pharmaceuticals

9.5.1. Drug Description

9.5.2. Regulatory Milestones

9.5.3. Safety and Efficacy

9.5.4. Product Profile

9.6. Kepivance: Swedish Orphan Biovitrum AB

9.6.1. Drug Description

9.6.2. Regulatory Milestones

9.6.3. Clinical Development

9.6.4. Safety and Efficacy

9.6.5. Product Profile

10. Emerging Therapies

10.1. Key cross competition- Emerging Therapies

10.2.               Dusquetide: Soligenix Inc.

10.2.1. Drug Description

10.2.2. Regulatory Milestones

10.2.3. Clinical Development

10.2.4. Safety and Efficacy

10.2.5. Product Profile

10.3.               EC-18: Enzychem Lifesciences Corporation

10.3.1. Drug Description

10.3.2. Regulatory Milestones

10.3.3. Clinical Development

10.3.4. Product Profile

10.4.               Rebamipide: Otsuka Pharmaceutical

10.4.1. Drug Description

10.4.2. Regulatory Milestones

10.4.3. Clinical Development

10.4.4. Safety and Efficacy

10.4.5. Product Profile

10.5.               RRx-001: EpicentRx

10.5.1. Drug Description

10.5.2. Clinical Development

10.5.3. Product Profile

10.6.               AG013: Oragenics Inc

10.6.1. Drug Description

10.6.2. Regulatory Milestones

10.6.3. Clinical Development

10.6.4. Safety and Efficacy

10.6.5. Product Profile

10.7.               GC4419: Galera Therapeutics

10.7.1. Drug Description

10.7.2. Regulatory Milestones

10.7.3. Clinical Development

10.7.4. Safety and Efficacy

10.7.5. Product Profile

10.8.               SAMITAL: Indena S.p.A

10.8.1. Drug Description

10.8.2. Clinical Development

10.8.3. Safety and Efficacy

10.8.4. Product Profile

10.9.               Mucomel: Spherium Biomed

10.9.1. Drug Description

10.9.2. Clinical Development

10.9.3. Safety and Efficacy

10.9.4. Product Profile

10.10. Brilacidin: Innovation Pharmaceuticals

10.10.1. Drug Description

10.10.2. Regulatory Milestones

10.10.3. Clinical Development

10.10.4. Safety and Efficacy

10.10.5. Product Profile

10.11. Validive: Monar Therapeutics

10.11.1. Drug Description

10.11.2. Regulatory Milestones

10.11.3. Clinical Development

10.11.4. Safety and Efficacy

10.11.5. Product Profile

10.12. Folotyn and Leucovorin: Spectrum Pharmaceuticals

10.12.1. Drug Description

10.12.2. Regulatory Milestones

10.12.3. Clinical Development

10.12.4. Product Profile

11. Key Findings

12. Market Size of Oral Mucositis in G8 Countries

13. United States Market Outlook

13.1. United States Market Size

13.1.1. Total Market size of Oral Mucositis

13.1.2. Market Size by Therapies

14. EU5Market Outlook

14.1. Germany Market Size

14.1.1. Total Market size of Oral Mucositis

14.1.2. Market Size by Therapies

14.2. France Market Size

14.2.1. Total Market size of Oral Mucositis

14.2.2. Market Size by Therapies

14.3. Italy Market Size

14.3.1. Total Market size of Oral Mucositis

14.3.2. Market Size by Therapies

14.4. Spain Market Size

14.4.1. Total Market size of Oral Mucositis

14.4.2. Market Size by Therapies

14.5. United Kingdom Market Size

14.5.1. Total Market size of Oral Mucositis

14.5.2. Market Size by Therapies

15. Japan Market Outlook

15.1. Japan Market Size

15.1.1. Total Market size of Oral Mucositis

15.1.2. Market Size by Therapies

16. China Market Outlook

16.1. China Market Size

16.1.1. Total Market size of Oral Mucositis

16.1.2. Market Size by Therapies

17. Market Drivers

18. Market Barriers

19. DelveInsight Capabilities

20. Appendix

20.1. Report Methodology

21. Disclaimer

22. About DelveInsight

Table 1: Patient-Related Risk Factors in Oral Mucositis

Table 2: Treatment-Related Risk Factors In Oral Mucositis

Table 3: Five biological stages of Mucositis

Table 4: Total Diagnosed Incident Population of Oral Mucositis in G8 Countries (2017-2028)

Table 5: Diagnosed Incident Population of Oral Mucositis in the US (2017-2028)

Table 6: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the US (2017-2028)

Table 7: Risk Factor Associated Diagnosed Incident Cases of OM in the US (2017-2028)

Table 8: Diagnosed Incident Population of Oral Mucositis in Germany (2017-2028)

Table 9: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Germany (2017-2028)

Table 10: Risk Factor Associated Diagnosed Incident Cases of OM in Germany (2017-2028)

Table 11: Diagnosed Incident Population of Oral Mucositis in France (2017-2028)

Table 12: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in France (2017-2028)

Table 13: Risk Factor Associated Diagnosed Incident Cases of OM in France (2017-2028)

Table 14: Diagnosed Incident Population of Oral Mucositis in Italy (2017-2028)

Table 15: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Italy (2017-2028)

Table 16: Risk Factor Associated Diagnosed Incident Cases of OM in Italy (2017-2028)

Table 17: Diagnosed Incident Population of Oral Mucositis in Spain (2017-2028)

Table 18: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Spain (2017-2028)

Table 19: Risk Factor Associated Diagnosed Incident Cases of OM in Spain (2017-2028)

Table 20: Diagnosed Incident Population of OM in the United Kingdom(2017-2028)

Table 21: Grade-Specific Diagnosed Incident Cases of OM in the United Kingdom (2017-2028)

Table 22: Risk Factor Associated Diagnosed Incident Cases of OM in the UK (2017-2028)

Table 23: Diagnosed Incident Population of Oral Mucositis in Japan (2017-2028)

Table 24: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Japan (2017-2028)

Table 25: Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Japan (2017-2028)

Table 26: Diagnosed Incident Population of Oral Mucositis in China (2017-2028)

Table 27: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in China (2017-2028)

Table 28: Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in China (2017-2028)

Table 29: Oral Cavity Mucositis Guideline Modified from MASCC/ISOO Clinical Practice Guidelines for Oral Mucositis

Table 30: Key cross competition- Marketed drugs

Table 31: Caphosol, Clinical Trial Description, 2018

Table 32: Episil, Clinical Trial Description, 2018

Table 33: Key cross competition- Emerging Therapies

Table 34: SGX942, Clinical Trial Description, 2018

Table 35: EC-18 Clinical Trial Description, 2018

Table 36: Rebamipide, Clinical Trial Description, 2018

Table 37: RRx001, Clinical Trial Description, 2018

Table 38: AG013, Clinical Trial Description, 2018

Table 39: GC4419, Clinical Trial Description, 2018

Table 40: SAMITAL, Clinical Trial Description, 2018

Table 41: Melatonin, Clinical Trial Description, 2018

Table 42: Brilacidin, Clinical Trial Description, 2018

Table 43: Clonidine Lauriad, Clinical Trial Description, 2018

Table 44: Folotyn and Leucovorin, Clinical Trial Description, 2018

Table 45: G8 Countries Market Size of Oral Mucositis in USD Million (2017-2028)

Table 46: Market Size of Oral Mucositis in the US, USD Million (2017-2028)

Table 47: Market size of OM by therapies in the US, in USD Million (2017-2028)

Table 48: Market Size of Oral Mucositis in Germany, USD Million (2017-2028)

Table 49: Market size of OM by therapies in Germany, in USD Million (2017-2028)

Table 50: Market Size of Oral Mucositis in France, USD Million (2017-2028)

Table 51: Market size of OM by therapies in France, in USD Million (2017-2028)

Table 52: Market Size of Oral Mucositis in Italy, USD Million (2017-2028)

Table 53: Market size of OM by therapies in Italy, in USD Million (2017-2028)

Table 54: Market Size of Oral Mucositis in Spain, USD Million (2017-2028)

Table 55: Market size of OM by therapies in Spain, in USD Million (2017-2028)

Table 56: Market Size of Oral Mucositis in the UK, USD Million (2017-2028)

Table 57: Market size of OM by therapies in the UK, in USD Million (2017-2028)

Table 58: Market Size of Oral Mucositis in Japan, USD Million (2017-2028)

Table 59: Market size of OM by therapies in Japan, in USD Million (2017-2028)

Table 60: Market Size of Oral Mucositis in China, USD Million (2017-2028)

Table 61: Market size of OM by therapies in China, in USD Million (2017-2028)

Figure 1: Symptoms of Oral Mucositis

Figure 2: Pathophysiology of Oral Mucositis

Figure 3: Neutrophil and Macrophage Polarization during the Early and Late Stages of Mucositis

Figure 4: Summary of Radiotherapy or chemotherapy - Induced Oral Mucositis pathobiology

Figure 5: Various Grades of Oral Mucositis

Figure 6: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events

Figure 7: Diagnosed Incident Population of Oral Mucositis in the US (2017-2028)

Figure 8: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the US (2017-2028)

Figure 9: Risk Factor Associated Diagnosed Incident Cases of OM in the US(2017-2028)

Figure 10: Diagnosed Incident Population of Oral Mucositis in Germany (2017-2028)

Figure 11: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Germany (2017-2028)

Figure 12: Risk Factor Associated Diagnosed Incident Cases of OM in Germany (2017-2028)

Figure 13: Diagnosed Incident Population of Oral Mucositis in France (2017-2028)

Figure 14: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in France (2017-2028)

Figure 15: Risk Factor Associated Diagnosed Incident Cases of OM in France (2017-2028)

Figure 16: Diagnosed Incident Population of Oral Mucositis in Italy (2017-2028)

Figure 17: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Italy (2017-2028)

Figure 18: Risk Factor Associated Diagnosed Incident Cases of OM in Italy (2017-2028)

Figure 19: Diagnosed Incident Population of Oral Mucositis in Spain (2017-2028)

Figure 20: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Spain (2017-2028)

Figure 21: Risk Factor Associated Diagnosed Incident Cases of OM in Spain (2017-2028)

Figure 22: Diagnosed Incident Population of OM in the United Kingdom (2017-2028)

Figure 23: Grade-Specific Diagnosed Incident Cases of OM in the United Kingdom (2017-2028)

Figure 24: Risk Factor Associated Diagnosed Incident Cases of OM in the UK (2017-2028)

Figure 25: Diagnosed Incident Population of Oral Mucositis in Japan (2017-2028)

Figure 26: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Japan (2017-2028)

Figure 27: Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Japan (2017-2028)

Figure 28: Diagnosed Incident Population of Oral Mucositis in China (2017-2028)

Figure 29: Grade-Specific Diagnosed Incident Cases of Oral Mucositis in China (2017-2028)

Figure 30: Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in China (2017-2028)

Figure 31: Management of Oral Mucositis

Figure 32: Unmet Needs for Oral Mucositis

Figure 33: G8 Countries Market Size of Oral Mucositis in USD Million (2017-2028)

Figure 34: Market Size of Oral Mucositis in the US, USD Million (2017-2028)

Figure 35: Market size of Oral Mucositis by therapies in the US, in USD Million (2017-2028)

Figure 36: Market Size of Oral Mucositis in Germany, USD Million (2017-2028)

Figure 37: Market size of Oral Mucositis by therapies in Germany, in USD Million (2017-2028)

Figure 38: Market Size of Oral Mucositis in France, USD Million (2017-2028)

Figure 39: Market size of Oral Mucositis by therapies in France, in USD Million (2017-2028)

Figure 40: Market Size of Oral Mucositis in Italy, USD Million (2017-2028)

Figure 41: Market size of Oral Mucositis by therapies in Italy, in USD Million (2017-2028)

Figure 42: Market Size of Oral Mucositis in Spain, USD Million (2017-2028)

Figure 43: Market size of Oral Mucositis by therapies in Spain, in USD Million (2017-2028)

Figure 44: Market Size of Oral Mucositis in the UK USD Million (2017-2028)

Figure 45: Market size of Oral Mucositis by therapies in the UK, in USD Million (2017-2028)

Figure 46: Market Size of Oral Mucositis in Japan, USD Million (2017-2028)

Figure 47: Market size of Oral Mucositis by therapies in Japan, in USD Million (2017-2028)

Figure 48: Market Size of Oral Mucositis in China, USD Million (2017-2028)

Figure 49: Market size of Oral Mucositis by therapies in China, in USD Million (2017-2028)

Figure 50: Market Drivers

Figure 51: Market Barriers

  • Tags:
  • Oral Mucositis (OM) market
  • Oral Mucositis (OM) market research
  • Oral Mucositis (OM) market insight
  • Oral Mucositis (OM) market trends
  • Oral Mucositis (OM) market forecast
  • Oral Mucositis (OM) market share
  • Oral Mucositis (OM) pipeline drugs
  • Oral Mucositis (OM) treatment algor...
  • Oral Mucositis (OM) drugs
  • Oral Mucositis (OM) sales forecasti...
  • Oral Mucositis (OM) market size
  • Oral Mucositis (OM) disease
  • Oral Mucositis (OM) epidemiology
  • Oral Mucositis (OM)
  • Oral Mucositis (OM) Companies
  • Oral Mucositis (OM) Pipeline

Forward to Friend

Need A Quote